Linical Co., Ltd. (2183) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Linical Co., Ltd. (2183:JPX), powered by AI.

Current Price
¥206
P/E Ratio
-8.6
Market Cap
4.7B
Sector
Healthcare
What is the Linical Co., Ltd. stock price forecast?

Linical Co., Ltd. is currently trading at ¥206. View real-time AI analysis on Alpha Lenz.

What is Linical Co., Ltd. insider trading activity?

View the latest insider trading data for Linical Co., Ltd. on Alpha Lenz.

What is Linical Co., Ltd.'s P/E ratio?

Linical Co., Ltd.'s P/E ratio is -8.6.

Linical Co., Ltd.

JPX · 2183
¥206-3(-1.44%)Market closedJPX regular session 09:00–15:00 JST
Ask about Linical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Linical Co., Ltd. trades at a P/E of -8.6 (undervalued) with modest ROE of -7.0%.

Ask for details

Company Overview

Linical Co., Ltd. is a global contract research organization that plays a vital role in the pharmaceutical and biotechnology industries. The company's primary function is to offer comprehensive drug development services, ranging from clinical trials to post-marketing surveillance. Headquartered in Japan, Linical Co., Ltd. operates on a multinational scale, facilitating seamless collaboration across regions in North America, Europe, and Asia. A notable feature of Linical is its specialization in oncology, central nervous system, and regenerative medicine trials. This focus allows it to contribute significantly to the advancement of cutting-edge medical treatments and therapies. By offering tailored services, the company enhances the efficiency and effectiveness of clinical development processes. In the financial markets, Linical Co., Ltd. is recognized for its stable presence in the healthcare sector, providing critical services that support drug approval processes and market entry strategies. This positions the company as a key player in the life sciences industry, fostering innovation and improving patient outcomes through its specialized and reliable research services. Linical's expertise and global outreach make it an indispensable partner for pharmaceutical companies aiming to navigate the complexities of drug development.

CEOMr. Kazuhiro Hatano
SectorHealthcare
IndustryBiotechnology
Employees598

Company Statistics

FY 2025

Profile

¥4,652,804,992Market Cap
¥10,437,032,000Revenue
0.00Shares Out
598Employees

Margins

22.76%Gross
0.46%EBITDA
-5.59%Operating
-4.91%Pre-Tax
-5.17%Net

Valuation

-8.63P/E
0.64P/B
0.45EV/Sales
-1.21EV/EBITDA
7.93P/FCF

Growth (CAGR)

-3.34%Rev 3Yr
-0.93%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-3.05%ROA
-6.96%ROE
-2.81%ROIC

Financial Health

¥7,039,571,000Cash & Cash Equivalents
¥2,482,275,000Net Debt
131.27%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Linical Co., Ltd. (ticker: 2183) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 598 employees. Market cap is $4.7B.

The current price is 206 with a P/E ratio of -8.63x and P/B of 0.64x.

ROE is -6.96% and operating margin is -5.59%. Annual revenue is $10.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Linical Co., Ltd. (2183) Stock Forecast 2026 ¥206 — Price, Financials & Analyst Targets | Alpha Lenz